SMARCA2 Degrader Program
Oncology
Pre-clinicalActive
Key Facts
About Atommap
Atommap is a private, pre-clinical stage biotech company pioneering a computational approach to drug discovery centered on simulating and harnessing the dynamic motion of proteins. Its proprietary platform integrates molecular dynamics, generative AI, and predictive computational assays to design novel therapeutic modalities, particularly molecular glues and targeted protein degraders, for historically undruggable targets. Founded by veterans from D. E. Shaw Research, Schrödinger, and Silicon Therapeutics, the company is advancing a pipeline in oncology, exemplified by case studies on mutant KRAS and SMARCA2.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |